The early-stage trial, performed within the United States, will check the vaccine in wholesome adults ages 65- 85.
Pfizer Inc stated on Monday it had dosed the primary affected person in a trial testing a flu vaccine primarily based on messenger RNA, the identical expertise used within the COVID-19 photographs made by the U.S. drugmaker and BioNTech.
The early-stage trial, performed within the United States, will check the vaccine in wholesome adults ages 65- 85.
“The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines,” stated Kathrin Jansen, head of vaccine analysis and improvement at Pfizer.
The study will check the protection and immune responses of the vaccine, in comparison with one other FDA-approved influenza vaccine.
